fromwww.theguardian.com
6 days agoRepurposed drug may extend survival in aggressive ovarian cancer, trial shows
The study published in the Lancet analyzed data from 381 patients with platinum-resistant ovarian cancer, revealing a 35% reduction in the risk of death among those treated with relacorilant compared to usual care.
Cancer

